Abstract
Preliminary evidence suggests that there is minimal withdrawal after the cessation of chronically administered buprenorphine and that opioid withdrawal symptoms are delayed compared with those of other opioids. The present study compared the time course and magnitude of buprenorphine withdrawal with a prototypical μ-opioid agonist, morphine. Healthy, out-of-treatment opioid-dependent residential volunteers (N = 7) were stabilized on either buprenorphine (32 mg/day i.m.) or morphine (120 mg/day i.m.) administered in four divided doses for 9 days. They then underwent an 18-day period of spontaneous withdrawal, during which four double-blind i.m. placebo injections were administered daily. Stabilization and spontaneous withdrawal were assessed for the second opioid using the same time course. Opioid withdrawal measures were collected eight times daily. Morphine withdrawal symptoms were significantly (P < 0.05) greater than those of buprenorphine withdrawal as measured by mean peak ratings of Clinical Opiate Withdrawal Scale (COWS), Subjective Opiate Withdrawal Scale (SOWS), all subscales of the Profile of Mood States (POMS), sick and pain (0–100) Visual Analog Scales, systolic and diastolic blood pressure, heart rate, respiratory rate, and pupil dilation. Peak ratings on COWS and SOWS occurred on day 2 of morphine withdrawal and were significantly greater than on day 2 of buprenorphine withdrawal. Subjective reports of morphine withdrawal resolved on average by day 7. There was minimal evidence of buprenorphine withdrawal on any measure. In conclusion, spontaneous withdrawal from high-dose buprenorphine appears subjectively and objectively milder compared with that of morphine for at least 18 days after drug cessation.
Footnotes
- Received September 12, 2013.
- Accepted November 2, 2013.
This project was funded by the National Institutes of Health National Institute on Drug Abuse [Grants R01-DA08045, K24-DA023186, T32-DA07209, and K23-DA029609]. The buprenorphine was provided by Reckitt-Benckiser Pharmaceuticals, Inc., through Research Triangle Institute, North Carolina.
Limited data from this manuscript were previously presented. Tompkins DA, Smith MT, Campbell CM, Edwards RR, and Strain EC (2013) A Prospective Study of Withdrawal-Associated Hyperalgesia (WAH) in Opioid-Dependent Volunteers. 32nd Annual Scientific Meeting of the American Pain Society; 8–10 May 2013; Tampa, FL; and Tompkins DA, Smith MT, Campbell CM, Mintzer MZ, and Strain EC (2013) Buprenorphine versus Morphine Withdrawal: A Controlled Comparison. 75th Annual Meeting of The College on Problems of Drug Dependence; 15–20 June 2013; San Diego, CA.
↵
This article has supplemental material available at jpet.aspetjournals.org.
- Copyright © 2013 by The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|